Core Viewpoint - The company is progressing with its clinical candidate CBT-004, a potential first-in-class ophthalmic drug, and is set to hold a crucial post-phase 2 clinical trial meeting with the FDA on December 10, 2025, to discuss the next steps in its development [1][2] Group 1: Clinical Trial Details - CBT-004 is a multi-kinase inhibitor targeting vascular endothelial growth factor receptors and platelet-derived growth factor receptors, aimed at treating vascularized eyelid lesions [1] - The phase 2 clinical trial for CBT-004 commenced in December 2023 and was completed in May 2025, demonstrating safety, tolerability, and efficacy in achieving primary and several secondary endpoints [1] Group 2: Regulatory and Future Steps - The upcoming meeting with the FDA is a significant milestone in the development of CBT-004, focusing on potential phase 3 clinical trial development and new drug application requirements [2] - The company plans to issue further announcements to keep shareholders and potential investors updated on the latest developments in its business [2]
拨康视云-B：Cloudbreak USA排定于12月10日与美国食品及药物管理局正式举行第2期临床试验后会议